7 May 2026

Coiled Therapeutics plc

("Coiled Therapeutics" or the "Company")

Appointment of Non-Executive Director

Leading oncologist joins the Board

Coiled Therapeutics plc (AIM: COIL), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers, announces the appointment of Dr Andrew Dean as Non-Executive Director with immediate effect.

Dr. Dean brings a wealth of leadership experience from clinical, academic, and corporate settings. He currently consults for GenesisCare, one of the world's largest integrated cancer care providers, and serves as the Head of Oncology at St John of God Subiaco Hospital in Western Australia, which operates the busiest clinical trials unit of any private hospital in the region. He is currently overseeing a number of studies into pancreatic, gastrointestinal and gynaecological cancers.  Under his leadership, the hospital was awarded the most outstanding site award by the Australasian GastroIntestinal Trials Group.

In addition to his clinical leadership, Dr. Dean serves as a board member for Valo Therapeutics, a clinical stage immunotherapy company that develops novel treatments for cancer and infectious diseases, and was the founder of the award-winning health information site, virtualmedicalcentre.com.

His extensive research background, which includes the molecular profiling of solid tumours and novel therapies for ovarian cancer, provides direct, relevant expertise that aligns with Coiled Therapeutics' precision oncology focus and its lead candidate, AO-252.

Commenting on the appointment, Sotirios Stergiopoulos, Chairman of Coiled Therapeutics, said: "We are delighted to welcome Andrew to the Board of Coiled Therapeutics. His vast experience as a clinical investigator and his deep expertise in the development of novel cancer therapies will be of considerable value as we advance our lead asset, AO-252.  Andrew's guidance will be invaluable as we progress through late-stage clinical studies and work to bring our transformative treatments to patients in need."

Andrew Dean, Non-Executive Director, added: "I am excited to be joining Coiled Therapeutics as a Non-Executive Director at such a pivotal moment in the Company's development. The recent clinical data for AO-252 is highly promising, demonstrating a significant clinical benefit and durable responses in a heavily pre-treated patient population. I am impressed by the innovative science behind the Company's TACC3 inhibitor and its unique immune-modulatory potential. I look forward to working with the Board and management team to help guide this promising technology through the next stages of development."

The following disclosures are made pursuant to Schedule 2(g) of the AIM Rules for Companies:

Dr Andrew Peter Dean, aged 63, currently holds or has held the following directorships or partnerships in the past five years:

Dr Andrew Dean currently holds 1,963,605 ordinary shares representing 0.46% of the Company's issued share capital and holds no options or warrants over the Company's ordinary shares.

There are no further disclosures required in accordance with AIM Rule 17 or Schedule 2(g) of the AIM Rules for Companies.

Enquiries:

About Coiled Therapeutics plc

Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884).  Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments.   The Company is also assessing its STAT-6 siRNA programme for immunology indications. Coiled Therapeutics is supported by a leadership team with a proven track record in drug development and strategic backing from A2A Pharmaceuticals.

About AO-252

AO-252 is a first-in-class, orally administered, brain-penetrant small molecule inhibitor of Transforming Acidic Coiled-Coil containing protein 3 (TACC3). TACC3 is a validated oncology target that is frequently overexpressed in many aggressive, hard-to-treat solid tumours but is dispensable in normal adult cells, providing a wide therapeutic window.

By selectively disrupting cancer-critical protein-protein interactions at the TACC3 C-terminal domain, AO-252 induces mitotic and replication stress, impairs DNA damage repair, and triggers cancer cell death. Notably, AO-252 has demonstrated the ability to cross the blood-brain barrier, addressing a significant unmet medical need for the treatment of brain metastases.

The asset is currently in an ongoing Phase I open-label dose-escalation study and early clinical signals have shown encouraging anti-tumour activity and a benign safety profile, with the Company planning to initiate dose expansion cohorts in lead indications, including prostate and ovarian cancer, during 2026.

For more information, please visit: www.coiledplc.com